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1. Introduction 
Glioblastoma multiforme (GBM) is the most common intracranial tumor and the most 
aggressive of all gliomas. These tumors are very heterogeneous both histopathological and 
genetic. There is no consistent theory today that can explain the etiology of glioblastoma. A 
number of factors, both environmental and genetic, have been suggested as potential causes 
of the tumor. It is possibly a combination of both which initiates and triggers the 
pathogenesis of tumor and the sequence of genetic alterations that lead to the genesis of 
neoplasia. They represent 60% of all astrocytic tumors and between 12-15% of all 
intracranial tumors. Three new patients per 100,000 people are diagnosed every year. 
Among its clinical features, age is particularly important for their development and 
survival. Although the tumor may arise at any age, most cases occur in adults (45-75 years). 
The average onset is between 53 and 62 years depending on the series (Kleihues et al., 2002, 
Ohgaki et al., 2004). The presence of tumor is much less frequent at earlier ages. Only 22% of 
cases involved patients younger than 45 years. It has been reported that cases between 0 and 
20 years old only represent 3-8% of the total (Dohrmann et al., 1976). This frequency of cases 
in the late adulthood may indicate the need for a relatively important period of time before 
the accumulation of genetic damage leading to tumor formation. As for the sex of the 
patients there is a preference for males, about 1.5 men for every woman (Kleihues et al., 
2002). 
Glioblastoma is an almost exclusively supratentorial tumor, affecting both cerebral 
hemispheres, with a similar spatial distribution to low-grade astrocytoma and anaplastic 
astrocytoma, being the most affected regions the frontal, temporal and parietal lobes 
(Dohrmann and et al., 1976; Russell & Rubinstein, 1989). The symptoms usually develop 
through a short history and in most cases do not exceed 3 months. The literature reflects that 
50% of cases are under the threshold of 3 months (Russell & Rubinstein, 1989). The speed of 
onset of symptoms can be explained by the rapid growth and by the high invasiveness and 
infiltration of the tumor. 
The three types of treatment (surgery, radiotherapy and chemotherapy) commonly used in 
the treatment of other malignancies, are also used as therapeutic strategies for glioblastoma. 
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Metastases are rarely found, probably due to the short survival time of these patients. The 
removal of a tumor produces large symptomatic relief and a slight increase in survival, but 
practically no cure. The high infiltration capacity of the tumor and the proximity of 
functionally important brain regions make surgical resection unable to eliminate all tumor 
cells, which produce relapses in short periods of time. Radiation therapy has also shown 
some efficacy in improving survival time. Likewise, chemotherapy strategies active in other 
tumors, have shown a relative efficacy in glioblastoma (Walker et al.., 1978, Walker et al., 
1980, Yung et al., 2000; Balañá et al., 2004). 
The biological aggressiveness of glioblastoma multiforme makes the survival of patients 
short, about a year, this being significantly lower than that observed for grade II and grade 
III astrocytomas (5 and 3 years respectively) (Jelsma & Bucy, 1969, Sant et al., 1988, Kallio et 
al., 1991, Ohgaki et al., 2004). 
From a histopathological point of view, glioblastoma is considered in the group of astrocytic 
gliomas and is the most malignant tumor in this group. According to the latest ranking of 
the World Health Organization (Louis et al., 2007), the tumor is classified as grade IV. It may 
show up as a lesion with high heterogeneity both intratumoral and intertumoral. This 
heterogeneity is represented by the variability of cell populations and their degree of 
differentiation. 
Glioblastoma may be the final stage of a progression that can result from less malignant 
lesions (Scherer, 1940). Low-grade astrocytoma, classified as grade II, is the first step on the 
scale of malignancy of astrocytomas, which already makes clear the invasive nature of the 
tumor. This tumor shows a slight increase in cellularity and diffuse compared to normal 
surrounding tissue. Vascularization in these cases becomes slightly hyperplasic in any of the 
three variants: fibrillary, protoplasmic and gemistocytic. Microscopically, despite the 
invasive nature, has low destructive power and distorts little the adjacent brain structures 
(Russell & Rubinstein, 2006).  
Although sharing some common ground with low-grade astrocytoma, anaplastic 
astrocytoma represents a further step in the progressive increase in cellularity,  reflected in 
the degree of anaplasia, the cellular and nuclear pleomorphism and increased proliferative 
rates, and already considered as malignant astrocytoma, grade III in the WHO classification 
(Louis et al., 2007). 
Finally, a last step in the malignant progression of the lesion, which reflects the changes 
with respect anaplastic astrocytoma, is morphologically expressed in a predominance of 
anaplastic cells and vascular proliferation with vascular hyperplasia and glomerular 
formations, besides the presence of necrosis 
 
 
Fig. 1. Histopathological features of glioblastoma with HE techniques. A) Anaplastic 
histological pattern. B) Pseudoglomerular vascular hyperplasia. C) Pseudoempalizada 
necrosis 
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The glioblastoma tumor cells differentially express glial fibrillary acidic protein (GFAP). 
GFAP is an antigen protein that is present in astroglial cells and is part of the structure of 
gliofilaments. The intensity and extent of GFAP expression is highly variable (Kleihues and 
Cavanee, 2000). Tumor cells usually retain some astrocytic differentiation and are strongly 
positive, especially gemistocytic. Undifferentiated small cells stain more weakly or are 
clearly negative. Multinucleated giant cells are the most variable in their expression of 
GFAP. Within a tumor, there may also coexist regions with no GFAP expression. As the 
tumor progresses, there is a tendency towards the lack of GFAP expression, but this fact is 
not considered to have prognostic value (Schmitt, 1983).  
In these tumors, Ki-67 rates are high ranging between 15-20% (Burger et al., 1986, 
Karamitopoulou et al., 1994). Both the number of mitosis and the proliferative rates vary 
depending on the tumor region studied. The spindle-like cells and the undifferentiated 
small cells seem to show a marked proliferative activity and may therefore have a more 
aggressive behavior. However, gemistocytic tumors show a lesser degree of proliferation. 
The determination of proliferative activity may be indicative of tumor behavior and provide 
additional information on the morphological diagnosis (Watanabe et al., 1997).  
 
 
Fig. 2. Morphological and immunohistochemical features of glioblastomas. A) Mitosis in 
tumor cells. B) Positive expression Ki-67/MIB-1. C) GFAP positive expression. 
According to the clinical concepts of Scherer (1940) with respect primary and secondary 
glioblastoma, most cases develop rapidly without clinical, radiological or morphological 
evidence of a less malignant precursor. This type of glioblastoma is considered primary or 
de novo glioblastoma, if also the diagnosis of glioblastoma was obtained in the first biopsy. 
In these cases, the tumor rapidly develops after a short history of less than 3 months in most 
cases. The diagnosis of secondary glioblastoma is performed only in cases with 
histopathological evidence of an earlier low-grade astrocytoma or anaplastic astrocytoma. In 
these cases, the tumor develops slowly and is considered to have arisen from the 
glioblastoma tumor progression of lower primary malignancy. Using these criteria, 
secondary glioblastomas are much less common than primary, reaching only 5% of the total 
(Dropcho & Soong, 1996, Ohgaki & Kleihues, 2005).  
Besides the difference in the diagnosis and progression of primary and secondary 
glioblastoma, there are also differences in the distribution of age and sex in the two types of 
tumors. Primary glioblastoma affects older patients with a mean age of 62, while secondary 
glioblastoma affects middle-aged patients with a mean of 45 years. The distribution between 
the sexes is also different, dominated by men in cases of primary glioblastoma (M:F 1.5), and 
women in secondary (F:M 0.65) (Ohgaki & Kleihues, 2005).  
A difference between the two subtypes is also observed in terms of survival. Primary 
glioblastoma has a median survival time shorter (4.7 months) than secondary glioblastoma 
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(7.8 months). This difference in survival may be due to the difference in the age at which 
they occur. In fact, there is no significant difference after an adjustment for age (Ohgaki & 
Kleihues, 2005).  
Primary and secondary glioblastomas are two tumor subtypes indistinguishable from a 
histopathological point of view.  
Taking these differences and clinical presentation, the group of Kleihues et al (1997), studied 
the distribution of molecular features known for glioblastomas, in each of these two 
subtypes. These authors performed a separation of primary and secondary glioblastomas 
based on two different histogenetic pathways. Amplification / overexpression of EGFR and 
TP53 mutation are considered the pillars of the two proposed genetic pathways for the 
formation of the two subtypes of glioblastomas. In principle, they were also considered 
mutually exclusive.  
Further studies were to define more precisely the presence of these molecular alterations. 
Amplification in primary glioblastomas and / or overexpression of EGFR occurred in about 
40% of cases. Mutations in TP53, however, are features of secondary glioblastomas and 
appeared in 65% of cases, being much less frequent in primary glioblastomas (28% of cases) 
(Ohgaki et al., 2004, Ohgaki & Kleihues, 2005). 
This chapter is organized as follow: In the 2nd section, we have realised a description on 
cytogenetic and molecular characteristics of glioblastoma. We analyzed the presence of 
numerical chromosomal aberrations by applying cytogenetic methods in cultured cells and 
centromeric DNA probes specific for chromosomes 7 and 10 in material proceeding from 
smear preparations; and we have studied the association between these parameters. Then, in 
the 3rd section, characteristics of epidermal growth factor receptor gene (EGFR) and its 
implication in the pathways of signalization are illustrated. We have investigated the 
expression of activated ERK1/2 in glioblastomas using western blot analysis and 
immunohistochemistry, and assessed the relationship between activated ERK1/2 and genetic 
factors such as EGFR amplification, TP53 mutation and alteration of 9p21 locus genes, as well 
as clinicopathological parameters. In section 4, we presented the histopathological and genetic 
findings of primary glioblastomas. The association between cases with EGFR gene 
amplification and cases without EGFR amplification with cytogenetic parameters, TP53 
mutations, MDM2 and CDK4 amplification, and cell cycle regulatory genes located at 9p21, 
was evaluated. A second aim of this study was to investigate the relationship between such 
genetic variations and clinical and pathological data. For last, in section 5, we investigated 
differences in the pattern of EGFR amplification in the glioblastoma. We performed FISH 
analysis with an EGFR probe in metaphases of primary cultured cells and in paraffin sections 
from 60 cases of primary glioblastomas. We also aimed to compare the EGFR copy number 
alterations, mRNA level and protein expression status and to correlate the FISH data with the 
clinical and histopathological parameters in the glioblastoma multiforme.        
2. Genetic hallmarks in glioblastomas  
The glioblastoma is characterized by intratumoral heterogeneity with regard to both 
histomorphology and genetic changes. Cytogenetically, the GBM displays highly complex 
karyotypes, with numerous structural and numerical aberrations, the presence of double 
minutes, as well as differences in ploidy level. The most common numerical chromosome 
aberrations are +7, +8, -9, -10, -13, -14, -22 and loss of a sex chromosome. Structural changes 
www.intechopen.com
Primary Glioblastoma with Different Patterns  
of EGFR Amplification and the Relationship with Gene Expression Profile 
 
489 
involve predominantly the following chromosome arms: 1q, 2q, 6q, 7p, 7q, 9p, 14q, 17p and 
18p (Jenkins et al., 1989, Bigner et al., 1990, Mitelman et al., 2004, Lopez-Gines et al., 2006). 
However, in vitro tissue culturing for karyotype analysis may result in the selective growth 
of cells with the highest proliferative activity, and these cells may not be representative of 
the primary tissue (Heim et al., 1989, Moertel et al., 1993). 
 
 
Fig. 3. Cytogenetic alterations in glioblastomas   
By minimizing any in vitro culture artefact, fluorescence in situ hybridization (FISH) may 
more accurately depict the chromosome aberrations in tissues, like the brain, in which 
cellular turnover is low. These studies showed different aneuploidy for chromosomes 1, 7, 
10, 17, X, and Y in astrocytomas, and in all of them the over-representation of chromosome 7 
and the under-representation of chromosome 10 are the most common in GBM (Arnoldus et 
al., 1992, Wernicke et al., 1997, Amalfitano et al., 2000, Koschny et al., 2002, Lopez-Gines et 
al., 2005). FISH on interphase cells is a powerful tool for detecting different chromosome 
aberrations, because it can detect chromosomal changes on a cell-by-cell basis. The FISH 
studies of GBM have also found, that trisomy for chromosome 7 and/or monosomy for 
chromosome 10 are the principal anomalies, but very few of them have been carried out on 
about smear preparations; this is a good material and a rapid method for to detection 
aneuploidy, with control by hematoxilyin-eosin for the presence of tumoral cells in the 
preparation. According to a few publications, the association between trisomy/polisomy 7 
and monosomy 10 is very different, 35-80% depending on the methods used (Steilen-Gimbel 
et al., 1996, Nishizaki et al., 2002, Lopez-Gines et al., 2005). The studies using karyotype 
analysis consider trisomy/polisomy 7 to be an early change and monosomy 10 as a 
progression-associated aberration (Rey et al., 1987, Bigner et al., 1990). On the contrary, 
other studies with FISH have suggested that in tumorigenesis, monosomy 10 may be an 
earlier change than the abnormalities in chromosome 7, because cases with monosomy 10 
but without trisomy 7 were observed (Steilen-Gimbel et al., 1996, Amalfitano et al., 2000). It 
is possible that the association of both is necessary in tumorigenesis of GBM.  
At the molecular level the glioblastoma multiforme has been studied extensively and the 
most commonly affected genes are the following:  
• Loss of heterozygosity (LOH): LOH on chromosome arm 10q is the most frequent gene 
alteration for both primary and secondary glioblastomas; it occurs in 60-90% of cases. 
This mutation appears to be specific for glioblastoma multiforme and is found rarely in 
other tumor grades. This mutation is associated with poor survival (Fujisawa et al., 
1999, Tada et al., 2001). 
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• Epidermal growth factor receptor (EGFR) gene: This oncogene is frequently 
amplified/overexpressed and mutated in glioblastoma. This alteration is observed in 
40-50% of these tumors (Wong et al., 1992, Ekstrand et al., 1994, Wang et al., 1994).  
• TP53 tumor suppressor gene: Appears to be deleted or altered in approximately 25-40% 
of all glioblastoma multiformes, more commonly in secondary glioblastoma (Yoon et 
al., 2001, Houiller et al.., 2006). 
• PTEN: Also known as MMAC and TEP1, encodes a tyrosine phosphatase located at 
band 10q23.3. PTEN mutations have been found in as many as 30% of glioblastomas, 
more commonly in primary glioblastoma (Karlbom et al., 1993, Lin et al., 1998). 
• MDM2: Amplification or overexpression of MDM2 is the second most common gene 
amplification in glioblastoma and is observed in 10-15% of patients. Some studies show 
that this mutation has been associated with a poor prognosis (Reifenberger et al., 1994). 
• Platelet-derived growth factor–alpha (PDGF-alpha) gene: The PDGF gene acts as a major 
mitogen for glial cells by binding to the PDGF receptor (PDGFR). Amplification or 
overexpression of PDGFR is typical (60%) in the pathway leading to secondary 
glioblastomas (Hermanson et al., 1992; Varela et al., 2004). 
• Additional genetic alterations in primary glioblastomas include INK4A deletions (30-
40%), and retinoblastoma (RB) gene protein alterations (Quelle et al., 1995, Stott et al., 
1998, Ichimura et al., 1996).  
 
 
Fig. 4. FISH analysis. A) Metaphase with trisomy 7 (painting probe). B) Metaphase with 
trisomy 7 (probe centromere of chromosome 7). C) Interphase nuclei with polysomy of 
chromosome 7. 
3. Epidermal growth factor receptor gene and pathways of signalization in 
glioblastoma multiforme 
The EGFR receptor is encoded by the gene c-erbB-1 or Her-1, located on chromosome 7 in 
the 7p12 region (Kondo et al., 1983). EGFR was the first receptor in which the ability to 
phosphorylate tyrosine residues in a portion of the molecule was detected. Their activation 
by the ligand leads to an increase in DNA synthesis, and consequently to an increase in cell 
proliferation and a decrease in apoptotic activity. This stimulation of cell division begins in 
the actions of its tyrosine kinase activity (Carpenter & Cohen, 1990). 
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The oncogenic properties of EGFR receptor are associated with a constitutive and 
uncontrolled increase in its phosphorylation catalytic activity. The reversible 
phosphorylation of proteins is one of the major mechanisms for protein regulation and for 
control of cell physiology. The phosphorylation of certain residues of a protein can regulate 
its activity, its interaction with other proteins, its structure and its location. Hence, protein 
kinases and phosphatases are an important part in its control. 
The kinases that phosphorylate tyrosine are involved in the initial steps of transmitting 
signals within the cell, resulting from ligand binding to the receptor (Ullrich & Schlessinger, 
1990).  
Phosphorylated tyrosine residues serve to the receptor as recruitment and association site 
for cytosolic proteins, which are activated in turn by new phosphorylations. The association 
of a protein to the receptor also produces the approximation of soluble proteins from the 
cytoplasm and thus facilitates this interaction. This will initiate the signaling pathways 
mediated by these molecules. 
Transduction pathways that are activated in this way include the route PI3 kinase/AKT, the 
Ras/MAP kinase, route c-myc, protein kinase C route and route STAT. All these paths 
induce the cell to activate transcription of specific genes that produce cell proliferation, 
apoptosis resistance, invasion, metastasis and angiogenesis, ultimately leading to malignant 
transformation (Dai et al., 2001; Arteaga, 2002, Rao & James, 2004). Therefore, the 
intracellular domain of the receptor has an extracellular signal transmitted to the cell 
nucleus via phosphorylation cascades.  
The signaling pathway RAS/RAF is altered in many tumor types, including glioblastomas. 
This signaling pathway through MAP kinases is involved in cell proliferation. ERK1 and 
ERK2 are the best studied kinases in solid tumors. ERK1/2 are activated by phosphorylation 
of tyrosine and threonine residues. Dual phosphorylation is necessary for full activation of 
ERK1/2. When ERK1/2 is activated migrates into the nucleus and phosphorylates 
transcription factors which affect the expression of certain genes and ultimately cell growth 
(Canagarajah et al., 1997, Jelinek et al., 1996). In our work we have observed that in many 
cases the amplification of EGFR is related to the dual activation of ERK1/2. Additionally, if 
the amplification of EGFR is linked to deletions or p16 gene methylation, the relationship 
with activation of ERK1/2 is more significant (Lopez-Gines et al., 2008). 
Major intracellular signaling pathways related to aging and apoptosis involve the enzyme 
phosphatidylinositol 3-kinase PI3-K. This kinase phosphorylates inositol phospholipids 
instead of proteins, and also acts on Akt by phosphorylation. Akt itself phosphorylates 
MDM2, which enters the nucleus where it accumulates, causing inhibition of TP53 (Honda 
et al., 1997; Roth et al., 1998). 
Nuclear factor NFkB is an important mediator in the regulation of TP53 and in the Akt 
signaling pathway. This regulation is achieved through an essential component of NFkB 
activation cascade, the protein RIP1 (death domain-containing receptor kinase interacting 
protein 1). RIP1 activates NFkB which causes an increase in MDM2 gene expression by 
inhibiting the action of TP53 (Park et al., 2009). 
Conversely, in the P13-K/PTEN/AKT pathway, PTEN tumor suppressor plays also an 
important role. This tumor gene encodes a phosphatase that dephosphorylates PI3-K, thus 
preventing the phosphorylation of Akt, and thus favoring TP53 action. PTEN produces a 
negative control on Akt kinase pathway, by its action opposite to PI3-K. Therefore, alterations 
in this gene have a negative effect on TP53 and therefore influence the aging processes and 
apoptosis, and the cell migration and tumor invasion (Li et al., 1997; Knobbe et al., 2002). 
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The genetic pathway TP53/MDM2 is also regulated by p14/ARF. p14 is a repressor of 
MDM2. If p14 does not exert its proper function, it will trigger an excess of free MDM2 and 
consequently inactivation of TP53. The alterations of these genes are diverse. p14, which acts 
as a suppressor gene, typically exhibits some deletions. MDM2, on the other hand, with 
oncogenic activity is often amplified whereas TP53 can show different types of mutations 
(Stott et al., 1998, Ichimura et al., 2000). 
Finally, another pathway affected in glioblastomas is p16/Rb/CDK4, which controls the G1-
S transition in the cell cycle and hence proliferation. In glioblastomas this pathway is 
impaired because p16, which normally acts as a tumor suppressor gene, has deletions. 
Additionally, CDK4 amplifications are also present, giving the cells oncogenic activity. The 
disturbance causes Rb to be continuously phosphorylated, and as a result there is an 
uncontrolled cell division (Reifenberger et al., 1994, Rollbrocker et al., 1996). 
All these molecules could be therapeutic targets in a tumor as aggressive as this that we are 
studying. 
 
 
Fig. 5. Pathways of signalization in glioblastoma multiforme 
Most gene amplification events in astrocytoma in general and in glioblastoma specifically, 
involve the EGFR gene. These gene amplification phenomena involve the duplication of 
certain regions of DNA that leads to the existence of multiple copies of a gene. EGFR 
amplification was an early genetic alteration involved in tumorigenesis of glioblastoma 
(Márquez et al., 2004). 
The vast majority of authors place the percentage of glioblastomas with EGFR amplification 
around 40-50% (Ekstrand et al., 1992, Diedrich et al., 1995, Shinojima et al., 2003). However, 
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some studies extend this range up to 73% (Márquez et al., 2004). These differences have been 
attributed to the different methodologies used (PCR, FISH, Southern blot). EGFR 
amplification has been observed in association with the increase in the number of copies of 
chromosome 7, both total or partial, which is the most common karyotypic abnormality 
found in glioblastoma (Hurtt et al., 1992, Rao & James, 2004). 
An increase in EGF receptor expression and its natural ligands has been observed using 
immunohistochemical techniques. This expression is not limited to the membrane, but also 
observed in the nucleus of tumor cells (Libermann et al., 1985, Ekstrand et al., 1991; 
Shinojima et al., 2003, Márquez et al., 2004). 
This increase coincides with the amplification of the gene encoding the receptor (Shinojima 
et al., 2003, Varela et al., 2004, Márquez et al., 2004, Lopez-Gines et al., 2005). On the 
contrary, no expression of this marker is present in normal tissue (Márquez et al., 2004). 
The combined increase in the expression of ligands and receptors has led to the assumption 
that there is a loop autocrine/paracrine growth which stimulates neoplasic growth. Thus, by 
the autocrine stimulation the cell induces autoproliferation in response to their own growth 
factors and by the paracrine stimulation there is induction of proliferation in response to 
factors secreted by neighboring cells and adjacent. In any case, there is an activation of the 
machinery of the cell cycle and uncontrolled cell proliferation. In fact there are several 
studies that support the importance of the system EGF/EGFR in the tumorigenesis of 
glioblastoma, due to the strong coexpression of EGF receptor and its respective ligands EGF 
and TGF-α (Ekstrand et al , 1991; Shinojima et al., 2003).  
Half of the glioblastoma cases with EGFR amplification also exhibit rearrangements of the 
gene, which results in a considerable variety of qualitative and structural alterations of the 
receptor, prompted by different mutations that can undergo the gene (Ekstrand et al., 1992, 
Shinojima et al., 2003, Rao & James, 2004). 
The gene sequences which are amplified in glioblastoma are frequently mutated and code 
protein variants shorter than the native protein (Frederick et al., 2000; Shinojima et al., 2003). 
These mutations can affect both the 5 'region and the 3' region of the gene. Thus, the mutant 
protein can be affected at both the extracellular and the intracellular domain. On the other 
hand, the reading frame is not usually affected by these mutations (Eley et al., 1998, 
Frederick et al., 2000). 
The most common rearrangement is a variant called EGFRvIII, a receptor with a molecular 
weight of 140-155 kDa that is expressed together with the normal 170 kDa protein (Sugawa 
et al., 1990, Sugawa et al., 1998; Wikstrand et al., 1998). This rearrangement has also been 
seen in other tumors where EGFR is also overexpressed (Eley et al., 1998; Arteaga, 2002). 
This mutation lacks a portion of the ligand binding extracellular domain as a result of 
genomic deletions that eliminate exons 2-7 in the EGFR mRNA (Frederick et al., 2000; 
Collins, 2002; Shinojima et al., 2003). This gives this form of the receptor a number of 
features distinct to those of the normal EGFR (Collins, 2002; Shinojima et al., 2003). 
4. Primary glioblastomas with and without EGFR amplification 
The pathogenic mechanisms leading to the development and progression of glioblastoma 
are still unclear. EGFR amplification has been identified as a genetic hallmark of primary 
glioblastoma and occurs in approximately 40-60% of primary glioblastomas, but rarely in 
secondary glioblastomas (Houiller et al., 2006, TCGA, 2008). Generally, primary 
glioblastomas with EGFR amplification show EGFR overexpression, and 70% to 90% of 
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those with EGFR overexpression have EGFR amplification (Liu et al., 2004). This 
oncogenetic pathway, is heavily involved in this variant of glioblastoma. However, there 
exist primary glioblastomas with no amplification/overexpression of the EGFR.   
In our previous works, EGFR amplification was observed in 53% of the tumors, and 80% of 
them presented EGFR overexpression. On the other hand, 47% of our primary glioblastomas 
showed no EGFR amplification and 67% of them showed no overexpression. We studied the 
association between cases with EGFR gene amplification and cases without EGFR 
amplification with cytogenetic parameters, TP53 mutations, MDM2 and CDK4 
amplification, and cell cycle regulatory genes located at 9p21. Furthermore, we investigated 
the relationship between such genetic variations and clinical and pathological data (Benito 
et al., 2009).  
At clinipathological level, the age distribution of cases with EGFR amplification closely 
follows that of patients with primary glioblastomas (60 years), and patients of less than 35 
years of age are more infrequent. In our results, the mean age of the group with EGFR 
amplification was 57.2 years and only one patient was under 35 years of age. However, the 
mean age for the group of cases without EGFR amplification was 49.8 years and four 
patients were under 35 years of age. The rest of the clinicopathological findings on primary 
glioblastomas with and without EGFR amplification did not show any significant 
differences, although, interestingly, patients with EGFR amplification survived for the 
shortest time.  
Cytogenetically, glioblastomas have shown many numerical and structural anomalies 
(Bigner et al., 1990, Lopez-Gines et al., 2006). In our study, the number of karyotypes with 
anomalies was greater in the group without EGFR amplification. Trisomy 7, monosomy 10 
and monosomy 22 were observed in both groups, and the structural alterations of 
chromosomes 1, 7 and 9 were more frequent in the first group. Every case with dmin had 
EGFR amplification.  
FISH on interphase cells is a powerful tool for detecting different chromosome aberrations, 
because it can detect chromosome changes on cell-by-cell bases. The FISH studies into 
primary glioblastomas have also found that trisomy for chromosome 7 and/or monosomy 
for chromosome 10 are the principal anomalies. In our cases, we found a high percentage 
(85%) of trisomy/polisomy and 70% of monosomy 10, higher in fact than those found by 
conventional cytogenetic analysis. Likewise, the association of both trisomy/polisomy 7 and 
monosomy 10 were present in 59% of the cases. In our study, both amplified and non-
amplified tumors showed trisomy/polysomy of chromosome 7 and monosomy of 
chromosome 10. This fact suggests that these alterations could be an initial event in the 
tumorigenesis of glioblastoma. 
At a molecular level, a close association between EGFR amplification and CDKN2A 
(INK4a/ARF) deletions is a frequent alteration in glioblastomas. Homozygous INK4a/ARF 
deletions were more frequent in primary than in secondary glioblastomas, but there was no 
significant difference in the overall frequency of these alterations (homozygous deletion and 
promoter methylation) between primary and secondary glioblastomas (Ohgaki & Kleihues, 
2007). In our results on primary glioblastomas, both  cases with and without EGFR 
amplification showed similar percentages of INK4a/ARF deletions, but the promoter 
methylation of INK4a was more frequent  in the group of cases with EGFR amplification.  As 
a consequence of CDKN2A deletions, there is a disruption of both RB1/CDK4/P16 and 
P53/MDM2/p14 pathways. MDM2 facilitates the ubiquitin-mediated degradation of p53, 
which is inhibited by p14/ARF. This fact probably explains why both MDM2 amplification 
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and INK4a/ARF are mutually exclusive. The amplification of MDM2 is present in less than 
10% of glioblastomas, exclusively in primary glioblastomas that lack a TP53 mutation 
(Houiller et al., 2006, Ohgaki & Kleihues, 2007). In our series, MDM2 amplification was 
present in 11% of the cases, all of them with EGFR amplification and without deletions of 
INK4a/ARF. CDK4 promotes the phosphorylation of the Rb protein and is inhibited by p16 
protein, a product of the INK4a tumor suppressor gene. Again, both alterations result in a 
redundant effect. In our cases, CDK4 amplification and INK4a/ARF deletions were mutually 
exclusive, and all cases except one were present with EGFR amplification. We also found 
tightly associated MDM2 and CDK4 amplifications, suggesting that both genes, which map 
close together to the same region on 12q13, are frequently included in the same amplicon. 
 
 
Table 1. Co-presence of genetic alterations in glioblastomas (expressed in %). 
Finally, the TP53 pathway plays a crucial role in the development of secondary 
glioblastomas, TP53 mutations being the first detectable genetic alteration. However, 
although this event also occurs in primary glioblastomas, it does so at a lower frequency 
(<30% of the cases). In our study, 18% of primary glioblastomas showed TP53 mutations. 
Furthermore, we have been found two glioblastomas showing both concurrent EGFR 
amplification and TP53 mutation. 
The first case, arising de novo in a 51-years old woman, expressed GFAP, S100, vimentin, and 
had p53_LI of 27%. EGFR was overexpressed. The cytogenetic analysis showed a 
hypertriploid complex karyotype with rearrangements of chromosomes 1, 7, 8, and 11, and 
dmin. FISH studies using centromeric DNA probes for chromosomes 7 and 10 showed 
trisomy 7 and monosomy 10 in the majority of the cells. Molecular biology showed EGFR 
amplification, and a C176R TP53 mutation; furthermore, aberrant hypermehylation in the 
promoter region of p14 gene was demonstrated. 
The second case arising three years later than a previous anaplastic astrocytoma in a 38-year 
old man, expressed GFAP, S-100, vimentin, and had p53_LI of 26%. EGFR was 
overexpressed. The karyotype was hypodiploid, with a t(9;18) and rearrangements of 
chromosomes 2, 13, and 14. Disomy 7/monosomy 10 was confirmed by FISH. At molecular 
level the tumor showed EGFR amplification and a R282W TP53 mutation. 
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Hypermethylation of promoter region of p16 gene was also observed. These cases showed, 
in common, monosomy of chromosome 10, hypermethylation in the INK4A locus, EGFR 
amplification and TP53 mutation (Gil-Benso et al., 2007). 
Our results suggest that, in primary glioblastomas, there exists a subgroup of cases closely 
linked with EGFR amplification. However, there is another subgroup of cases without EGFR 
amplification with some different clinical and genetic characteristics. This second group 
might include the increased activation or expression of other growth factor receptors 
observed in these tumors such as PDGFR or IGFR, although they are only amplified in a low 
percentage of cases. 
 
 
Table 2. Characteristics of glioblastomas with and without EGFR amplification 
5. Patterns of EGFR amplification and gene expression profile 
Amplifications are mutations that result in multiple copies of genes in chromosomal regions 
(amplicons) and induce overexpression in cancer cells. The amount of overexpressed genes 
in amplified regions varies between different types of cancers, and gene expression in 
general was significantly regulated by DNA copy number alterations (Schwab, 1998, 
Myllykangas & Knuutila, 2006). Chromosomal abnormalities associated with DNA 
amplification can be organized as extrachromosomal copies, called double minutes (dmin);  
in tandem arrays as head-to-tail or inverted repeats within a chromosome, often forming a 
cytologically visible, homogeneously staining region (HSR); or distributed at various 
locations in the genome (distributed insertions) (Schwab,1998, Kuwahara et al., 2004, 
Albertson, 2006). MYCN, ERBB2 and EGFR are the most frequently amplified genes in 
cancers. 
According to the breakage-fusion-bridge (BFB) model of amplification, the initiating event 
in HSR formation is double chromatid breakage at a fragile site or telomere erosion 
(Coquelle et al., 1997, Murnane & Sabatier, 2004), fused sister chromatids and breaking of 
the anaphase bridges (Shimizu et al., 2005). BFB cycles could then result in inverted 
amplified structures (Toledo et al., 1992), and the mutated sister chromatids are distributed 
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to the daughter cells giving rise to intra-tumor heterogeneity (Gisselsson et al., 2000). Gene 
amplifications are also acquired by selection and unequal segregation of circular 
extrachromosomal chromatin (dmin and episomes). These elements are formed by looping 
out from the chromosomes. Dmin and episomes may also relocate in the genome after DNA 
double-stranded breaks to form HSR or distributed insertions (Schwab, 1999, Kuwahara et 
al., 2004). Instead of these above-mentioned mechanisms, N-myc duplication located at 2p24 
has been described in neuroblastoma cell lines, as studied by FISH (Corvi et al., 1995). Large 
direct duplications may arise by unequal sister-chromatid exchange and appear to play a 
role during the initial stages in amplification. It is unclear whether duplication represents a 
prelude to amplification or an alternative pathway for activating the oncogenic potential of 
MYC. (Corvi et al., 1995, Schwab, 2004).  
 
 
Fig. 6. Patterns of gene amplification: dmin, hsr and genomic insertion. 
The first evidence of gene amplification in glioblastoma was provided by cytogenetic 
analyses which exhibited the presence of dmin, found in up to 50% of tumors (Bigner & 
Volgelstein, 1990; Thiel et al., 1992).  
Molecular studies demonstrated the amplification of several genes in these tumors, 
especially of the EGFR gene; the amplified sequences were found located on dmin in a small 
number of cases, by in situ hybridization of tumor metaphases (Muleris et al., 1994, Vogt et 
al., 2004). However, studies by FISH in interphase nuclei are more frequent, displaying a 
considerable heterogeneity of EGFR copy number (Sauter et al., 1996, Vogt et al., 2004, 
Layfield et al., 2006, Mizoguchi et al., 2006). The large fraction of cases presenting a diffuse 
rather than a clustered pattern of amplification within single cells supports the notion that 
the most common pattern of EGFR amplification in glioblastoma biopsies is as double 
minutes, which ranged in size from 0.7 to 2.1 Mb and in level of amplification from 8-to-63-
fold (Vogt et al., 2004). The FISH signals differed from case to case, intense and multiple, 
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double, faint and single. This suggests the complexity of dmin formation since both their 
size and the number of EGFR copies they contain, vary. Cell to cell variations are also likely 
to exist for a given tumor (Sauter et al., 1996). 
Molecular screening for gene amplification revealed the frequent amplification of the EGFR, 
observed in about 35%-70% of glioblastomas (Sauter et al., 1996, Okada et al., 2003, Ohgaki 
and Kleihues, 2007). Differences in the frequency of EGFR amplification are most likely due 
to the different methods used, such as Southern blot, polymerase chain reaction (PCR), and 
fluorescent in situ hybridization. 
EGFR protein overexpresssion is usually associated with gene amplification in 
glioblastomas and these two parameters have been studied as a potential prognostic 
indicator (Shinojima et al., 2003, Layfield et al., 2006). The majority of GBMs with EGFR 
amplification also contain the mutant EGFR gene, EGFRvIII, which is characterized by the 
deletion of exons 2–7, resulting in an in frame deletion variant that has a truncated 
extracellular domain with ligand-independent constitutive activity.  
Overexpression of wild-type EGFR was not found to be an independent prognostic 
indicator of survival in several studies, and one study was inconclusive (Simmons et al., 
2001, Shinojima et al., 2003). Four studies identified EGFR as a negative prognostic indicator 
of survival, one of which showed the effect only in patients younger than 45. In some of 
these studies, analysis was limited by small sample size, uncharacterized extent of surgical 
resection, and variable postoperative treatment. The prognostic impact of EGFRvIII has not 
been as extensively studied, but in the study that addressed this variable, the presence of 
EGFRvIII was found to be an independent and significant unfavorable prognosticator of 
survival (Ekstrand et al., 1991, Simmons et al., Smith et al., 2001, Arteaga et al., 2002, 
Marquez et al., 2004). EGFR amplification and EGFRvIII have been shown to increase glioma 
proliferation and invasion in vitro; therefore logically EGFR and/or EGFRvIII expression 
could exhibit a proclivity towards the development of multifocal disease, gliomatosis cerebri 
or ependymal seeding.  
In our study we performed FISH analysis with an EGFR specific probe in metaphases of 
primary cultured cells and in paraffin sections from 60 cases of primary glioblastomas, in 
order to investigate differences in the pattern of EGFR amplification in this tumor. We 
compared the EGFR copy number alterations and gene expression with the clinical and 
histopathological parameters in this subset of tumors.   
5.1 Methodology 
5.1.1 Histopathological study 
Tissue removed from the patient during the surgical resection was divided into three 
fragments, one for histopathological and immunohistochemical study, one for culture, and 
the other was frozen and stored at -80ºC until molecular analysis and DNA extraction were 
performed. 
The tumoral tissue was fixed in neutral-buffered formalin during the first 48h, embedded in 
paraffin, sectioned and stained with HE. The samples were categorized according to the 
WHO classification and diagnosed as glioblastoma multiforme (Louis et al., 2007). Mitotic 
index values were obtained by counting the total number of mitotic figures in the tumor 
cells in 20 high-power fields (HPF) and in two different sections. The values are the mean 
number of mitoses per 10 HPF. 
The immunohistochemical study was performed on paraffin-embedded sections using the 
avidin-biotin peroxidase method. The study was carried out with antibodies against glial 
www.intechopen.com
Primary Glioblastoma with Different Patterns  
of EGFR Amplification and the Relationship with Gene Expression Profile 
 
499 
fibrillary acidic protein (GFAP) (Dako, Glostrup, Denmark), Ki-67 (MIB-1, Dako, Glostrup, 
Denmark), p53 (Dako, Glostrup, Denmark), and monoclonal mouse antihuman EGFR (clone 
H11, Dako, Glostrup, Denmark) that recognizes the wild-type EGFR and the deletion 
mutant form of the receptor (EGFRvIII). 
Proliferation index was evaluated using MIB-1 antibody staining, and was calculated by 
determining the percentage of immunopositive nuclei. EGFR expression was scored 
according to the intensity of staining and number of staining cells, as: 0 (no staining), 1 (light 
or focal), 2 (moderate) and 3 (strong). Scores of 0 or 1 were defined as no overexpression; 
scores of 2 and 3 as overexpression (Shinojima et al., 2003).  
5.1.2 Cytogenetic analysis and fluorescence in situ hybridization 
Cytogenetic analyses were performed by short-term culture of the tumors. Fresh tumor 
samples were disaggregated with 2mg/mL of collagenase II. The cells were seeded in flasks 
using RPMI-1640 medium supplemented with 20% foetal bovine serum, L- glutamine, and 
antibiotics. The cells were processed after 72 h of culture by a standard technique. Air dried 
slides were banded by trypsin-Giemsa. Karyotypic analyses were performed according to 
ISCN (1995). 
 
 
Fig. 7. Cultured cells of glioblastoma 
To evaluate EGFR gene status, dual-color FISH was performed on cultured cells and on 
paraffin sections. FISH was carried out using the LSR EGFR Spectrum Orange/CEP 7 
Spectrum Green Probe from Vysis (Abbott Laboratories, Downers Grove, IL, USA. Cat. No. 
32-191053). 
 
 
 
Fig. 8. LSR EGFR Spectrum Orange/CEP 7 Spectrum Green Probe (Vysis). 
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Cultured cells were treated with Colcemid (0.02 µg/mL) (Gibco BRL, Grand Island, NY, 
USA) for 80 minutes, and chromosomes were prepared by conventional fixation. The 
paraffin embedded tissues were cut at 5-μm and mounted on Superfrost/Plus microscope 
slides. Hybridizations were performed according to the instructions that accompany the 
probe. Counterstaining of nuclei was carried out using DAPI. The fluorescent signal was 
detected using a photomicroscope Axioplan 2 and Axiophot 2 (Zeiss) equipped with a set of 
the appropriate filters. Signals were counted in 100-200 cultured cell nuclei, in all the 
possible metaphases and in 100 non-overlapping tumor cell nuclei in the paraffin sections. 
The mean signal number for the EGFR gene and CEP 7 was calculated for each case, as well 
as the EGFR gene/CEP 7 ratio. The EGFR gene was scored as amplified in individual cells 
when the EGFR/control signal ratio was greater than 2 (Layfield et al., 2006). 
5.1.3 Real-time quantitative PCR 
Tumor DNA was extracted from 10-15 mg using DNeasy kit extraction (Qiagen, Valencia, 
CA). Quantitative PCR was performed using an ABI Prism 7900 HT Fast Real-Time PCR 
System (Applied Biosystem, Foster City, CA) to analyze EGFR copy number. Primer 
sequences for EGFR were: forward GTGCAGATCGCAAAGGTAATCAG; reverse 
GCAGACCGCATGT GAGGAT; and probe FAM-CCCCTCCCCGTATCTC-MGB. Primer 
sequences for RNase P and GAPDH used as references genes were purchased to TaqMan 
RNase P and GAPDH Detection Reagents  (P/N: 4316831).  
Target and reference genes were amplified in separate wells. Each 20 µl assay contained 20 
ng of genomic DNA, 900 nM each of forward and reverse primers for the gene (RNasa P, and 
GAPDH as reference gene, and EGFR as target gene), and 250 nM of labelled gene specific 
probe in 1x TaqMan Universal PCR Master Mix. The TaqMan universal PCR Master Mix 
(Applied Biosystems) contained AmpliTaq Gold DNA polymerase, AmpErase uracyl-N-
Glycosylase, deoxynucleotide triphospates with dUTP that replace dTTP, and optimized 
buffers.  
Individual samples were run in triplicate. PCR conditions were: 2 min at 50ºC (initial 
incubation for activate AmpErase), 10 min at 95ºC (Activation of AmpliTaq Gold DNA 
Polymerase) followed by 40 cycles of 15 sec at 95ºC (melt) and 1 min at 60ºC 
(anneal/extend). Real Time data was collected by the SDS 2.1 software. Each replicate was 
normalized to reference gene (RNasa P and GAPDH) to obtain ΔCt, and average ΔCt for each 
sample (from the 3 replicates) was calculated. All samples were normalized to a calibrator 
sample to determine ΔΔCt. Relative quantity is 2 –ΔΔCt , and copy number is 2x (Relative 
quantity) (Livak & Schmittgen, 2001). 
Theoretically, a normal sample has two copies for each gene. Such an assumption is right in 
cell lines, but taking into consideration that human tumor tissue samples may be 
contaminated by normal cells, we use a copy number range approach and consider: 
Homozigous Deletion (HD) 0 - 0.4; Borderline HD-Loss of Heterozigosity (LOH) > 0.4 - 0.6; 
LOH > 0.6 – 1.4; Borderline LOH-Normal > 1.4 – 1.6; Normal > 1.6 - 2.4; Borderline 
Amplification > 2.4 – 2.6; and Amplification > 2.6. 
5.1.4 Single nucleotide polymorphism (SNPs) array analysis for assessment of EGFR 
copy number status 
Nucleic Acid Isolation and microarray experiment: Fresh frozen tumor tissues (10-20 mg) 
from patients with glioblastoma were used to extract high molecular weight, genomic DNA 
using DNeasy kit extraction (Qiagen, Valencia, CA). DNA quality was assessed by 
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electrophoresis in 1% of agarose gel. Two hundred and fifty DNA nanograms were used for 
hybridization on Genechip Human Mapping 100K as recommended by the manufacturer 
(Affymetrix, Santa Clara, CA). The mapping 100K set provides a broad coverage of the 
human genome (92%), with an average distance between SNPs of 23.6 Kb. This set includes 
two arrays, each with more than 50,000 SNPs. The processing was performed following the 
manufacturer’s guidelines. Arrays were scanned by means of a GeneChip Scanner 3000, and 
GeneChip Operating software was used to define Absent or Present Call and generate CEL 
files. 
Data Analysis: CEL files were imported into dChipSNP arrays analysis software (Lin et al., 
2004). Arrays were normalized against the array with median overall intensity (Baseline 
array) employing the Invariant set normalization method (Li & Wong 2001a). Probe set signal 
intensity was obtained by using a model based on expression index (PM/MM) method (Li & 
Wong, 2001b). Average array call rate was > 95 %. We employ a Hidden-Markov model to 
identify LOH regions from unpaired tumor samples, taking into account SNP intermarker 
distance, SNP heterozigosity rates, and the haplotype structure of the genome (Beroukhim 
et al., 2006). We used 60 CEPH parents as normal reference genotype and we removed 
inferred LOH regions consistent with 95% of homozygous markers in normal reference 
samples. Copy number alterations at each SNP locus were determined using the probe level 
signal intensity data. Reference signal distribution was obtained using a trimmed analysis 
with 80 % of the samples.  
5.1.5 EGFR mRNA expression 
Nucleic acid isolation: RNA was extracted from 19 glioblastoma samples. Five pilocytic 
astrocytomas without EGFR amplification were used as reference. For total RNA extraction, 
10-20 mg of frozen tumor samples were homogenized with Ultra Turrax and total RNA was 
isolated using mirVANA kit (Ambion Inc, Austin, TX) following the manufacturer’s 
instructions. Purified RNA was quantified by UV absorbance at 260 and 280 nm and RNA 
quality was assessed using a spectrophotometer and Agilent 2100 Bioanalyzer (Agilent 
Technologies, Palo Alto, CA). Samples with 28S/18S ratio of ≥ 1.1 and no evidence of 
ribosomal peak degradation were included. 
Microarray experiments: Total RNA (1-15µg) was used to generate double-stranded cDNA. 
cDNA synthesis and cRNA labelling were performed using the protocol for one-cycle cDNA 
synthesis. Biotin-labeled cRNA (20 µg) was fragmented and hybridized overnight to 
Affymetrix HU133plus2.0 genechip. Protocols were performed as recommended by 
Affymetrix. Arrays were washed, stained with streptavidin phycoerythrin and scanned to 
generate an image file. Scan quality was assessed by the inspection of visible microarray 
artifacts, grid placement, background intensity, and housekeeping gene expression. 
GeneChip operating software (GCOS) was used to define Absent or Present Call and 
generate CEL files. Arrays with < 30% “Present” call for the 47,000 probe sets and signal 
3´/5´ratio of GDAPH control 0.5 ≤ ratio ≤ 4.5 were omitted.  
Data analysis: CEL files were imported into dCHIP program. Arrays were normalized 
against the array with median overall intensity (Baseline array) employing the Invariant set 
normalization method (Li & Wong 2001a).  Probeset signal intensity was obtained by using 
a model based on expression index (PM/MM) method (Li & Wong, 2001b). EGFR probesets 
with Present Call and expression level ≥10 in ≥ 45 % samples were selected. Probesets that 
pass established criteria were: 1565484_x_at; 201983_s_at; 201984_s_at; 211551_at; 
211607_x_at. 
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5.1.6 Statistical analysis 
In this study we used no parametric test for Ki67 levels, EGFR copy number, EGFR 
transcript expression, and percentage of cells found to be EGFR amplification by FISH. First, 
the Kruskal-Wallis test was used to assess significant differences among established groups, 
and then the comparisons among the pairs of groups were assessed by means of the Mann-
Whitney U test. We used the Bonferroni method to correct the p-values in order to avoid 
type I error. 
Pearson´s coefficient was used to assess the significant correlation between: EGFR copy 
number measured by qPCR, EGFR transcript expression and percentage of EGFR positive 
cells measured by FISH. The significance of the differential protein expression was 
contrasted by comparing the EGFR amplification type using Fischer´s exact test (one-tailed). 
Survival curves for amplification types, KPS groups (≤80, >80), and age (<55, ≥55 years) 
were evaluated by the Kaplan-Meier method and were compared with the log-rank test. The 
statistical tests significance was determined at p-value ≤ 0.05. The analysis was performed 
with SPSS 15.0 software (SPSS Inc., Chicago, IL). 
5.2 Levels of EGFR amplification in glioblastoma 
Sixty glioblastomas were analyzed successfully by FISH in cultured cells and paraffin 
sections. We have analyzed the type of EGFR amplification, the fraction of amplified cells, 
and the number of signals of EGFR in each tumor. 
 On basis of the EGFR status, the gene copy number and the type of amplification, the cases 
were categorized into three groups: GBM-h: high level EGFR gene amplification and dmin, 
GBM-l: low level EGFR gene amplification and insertions, and GBM-n: no EGFR gene 
amplification (Lopez-Gines et al., 2010).  
GBM-h: The 47% of the cases was included in this group. The 50% of patients were male 
and 50% female. Patient age ranged from 38 to 72, with a mean age of 56 years. Survival 
ranged from 1 to 24 months, with a mean of 9 months. 
Histologically, all tumors demonstrated features of glioblastoma with pleomorphic, 
astrocytic tumor cells, prominent microvascular proliferation, and necrosis. In every case, 
the expression of GFAP was confirmed in the neoplastic cells. The number of mitoses 
ranged between 1 and 20, with a mean of 7. The mean Ki-67 of the tumors was 38%; range: 
10-80%.  
The type of amplification was dmin with a variable number of copies affecting over 25% of 
the cells in most cases. Only two cases contained less than 10% of amplified cells in paraffin 
sections. 
By using SNP arrays, we inferred the presence of frequent copy number gains in the region 
of the EGFR locus. In tumor samples, an excess of EGFR gene copies was identified by copy 
number variation from the reference set and from the copy number of the control samples. 
Gene copy numbers at 7p12.1 were validated by quantitative PCR. Every case showed a 
strong correlation of these values with the copies demonstrated by FISH (Pearson’s 
correlation coefficient= 0.77; p-value≤ 0.01).  
Gene expression have a significant, positive correlation between the EGFR copy number and 
the transcript gene expression (Pearson’s correlation coefficient = 0.75; p-value≤ 0.01). The 
higher percentage of cases of amplified EGFR detected by FISH was correlated with a higher 
gene expression (Pearson’s correlation coefficient = 0.85; p-value≤ 0.01). 
The EGFR protein expression was evaluated by immunohistochemistry. Cases with a high 
level of amplification, manifested EGFR overexpression (except in two cases). 
www.intechopen.com
Primary Glioblastoma with Different Patterns  
of EGFR Amplification and the Relationship with Gene Expression Profile 
 
503 
 
Fig. 9. High-level of amplification of the EGFR present in GBM-h group. Probe for EGFR and 
centromere 7 were labelled with red and green respectively.  A) Interphase nuclei of 
cultured cells. B) Metaphase showing trisomy 7 and EGFR amplification as dmin C) Nuclei 
in paraffin sections showing high level of amplification. Probe for EGFR and centromere 7 
were labelled with red and green respectively. D) Immunoreactivity for EGFR: Strong 
staining.  
    
Fig. 10. Low-level of amplification of the EGFR present in GBM-l group. A) Different 
interphase nuclei of cultured cells showing low-level (arrow) of amplification. B) Metaphase 
spread with extra copies of EGFR inserted in p and q arms of chromosomes 7. C) Tumoral 
cells in paraffin section with low-level amplification/copy number gains with other cells 
exhibiting a normal copy number of the EGFR gene. D) Immunoreactivity for EGFR with 
focal staining. 
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GBM-l: The 21% of the cases was included in this group. The 69% of patients were male and 
31% female. Patient age ranged from 24 to 73, with a mean age of 48 years. Survival ranged 
from 3 to 23 months, with a mean of 12 months. 
Histologically, all tumors demonstrated features of glioblastoma with pleomorphic, 
astrocytic tumor cells, prominent microvascular proliferation, and necrosis. In every case, 
the expression of GFAP was confirmed in the neoplastic cells. The number of mitoses 
ranged between 0 and 20, with a mean of 4. The mean Ki-67 of the tumors was 24%; range: 
5-50%. The type of amplification showed extra copies of EGFR inserted in different locus of 
chromosome 7, both in p and q arms. In this form of amplification, the number of copies was 
small, and the percentage of cells with  EGFR amplification, rarely affects more than 15% of 
the cells. These cases presented low values validated by quantitative PCR.  The increase in 
mRNA caused by amplification is not always proportional to the number of gene copies. 
Non increase of RNA expression was found in this group. The EGFR protein expression was 
variable, only one third of the cases scored EGFR overexpression. 
GBM-n: The 32% of the cases was included in this group. The 63% of patients were male 
and 37% female. Patient age ranged from 22 to 76, with a mean age of 49 years. Survival 
ranged from 3 to 24 months, with a mean of 11 months. 
Histologically, all tumors demonstrated features of glioblastoma with pleomorphic, 
astrocytic tumor cells, prominent microvascular proliferation, and necrosis. In every case, 
the expression of GFAP was confirmed in the neoplastic cells. The number of mitoses 
ranged between 0 and 10, with a mean of 3.The mean Ki-67 of the tumors was 23%; range: 5-
50%. 
These cases without EGFR amplification presented the values of quantitave PCR nearly 2, 
and non increase of RNA expression was found. The immunohistochemistry analysis 
showed no overexpression in 79% of cases and overexpression in 21% of cases. 
 
 
Fig. 11. No amplification of the EGFR present in GBM-n group. A) Different interphase 
nuclei of cultured cells showing no amplification. B) Metaphases spread with three 
centromeres of chromosome 7 and three copies of EGFR. C) Non-amplified tumoral cells of 
paraffin sections. D) No immunoexpression for EGFR 
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On the basis of these results, the model of amplification of group GBM-l could correspond to 
a variant of the distributed insertion mechanism, or a consequence of a process of 
duplication like the one demonstrated in neuroblastoma cell lines (Corvi et al., 1995), and 
we suggest that this mechanism could be considered as an early stage of amplification in 
glioblastoma. This hypothesis is corroborated by the findings of both status of amplification, 
dmin, and extra copies located in chromosome 7, in two cases. In glioblastomas, the cut-
points that define amplification are controversial (Smith et al., 2001, Layfield et al., 2006), 
although the most commonly accepted criteria is that EGFR amplification exists when the 
EGFR gene/chromosome per cell ratio was ≥2, or ≥15 copies of EGFR per cell in ≥10% of 
analyzed cells (Capuzzo et al., 2005, Nagasaka et al., 2007).  
 
 
Fig. 12. Model of amplification of EGFR correspond to a variant of the distributed insertion 
mechanism. 
In addition, there was considerable heterogeneity in the centromere 7 (CEP7) copy number 
in these tumors. The relationship between trisomy/polysomy of chromosome 7 and EGFR 
gene amplification has been analyzed. In our study, both amplified and non-amplified 
tumors showed trisomy/polysomy of chromosome 7. This fact suggests that this alteration 
could be an initial event in the tumorigenesis of glioblastoma. 
 
 
Table 3. Characterization of the three types of EGFR amplification found in glioblastoma 
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5.3 Statistical correlation of EGFR copy alterations with clinicopathological 
parameters 
The Kruskal Wallis test was used to assess the differences among the three amplification 
groups and it showed significant differences in the percentage of cells with positive EGFR 
amplification detected by FISH, the EGFR copy number quantified by PCR, and the EGFR 
transcript expression assessed by microarrays (p-value ≤ 0.01). In the percentage of EGFR 
positive cells and EGFR copy number, all bilateral comparisons of the  three amplification 
groups showed statistically significant differences, after the Bonferroni correction (GBM-h 
vs GBM-l, GBM-h vs GBM-n, GBM-l vs GBM-n) (p-value ≤ 0.01). The EGFR expression 
values of amplification types GBM-h and GBM-l were statistically significant after the 
Bonferroni correction (p-value ≤ 0.01). No significant differences were found between types 
GBM-l and GBM-n. The mean Ki-67 value of group GBM-h exhibited statistically significant 
differences with respect the rest (p-value < 0.05). Ki-67 mean values for the different groups 
were 38% for the GBM-h group, 24% for the GBM-l group and 23% for the GBM-n group. 
None of the survival curves showed any significant differences in established groups 
according to EGFR amplification type, and age (<55, ≥55 years). As we expected, younger 
patients (<55 years) showed a slightly higher survival rate. Interestingly, patients with EGFR 
amplification type GBM-h survived for the shortest time, a mean of 9 months. 
Amplification in general and amplicons in particular are important for both prognosis and 
targeted therapies. Specific amplicons, such as MYCN in neuroblastomas, and MYC and 
ERBB2 in breast cancer, also have prognostic significance (Albertson, 2006). EGFR 
amplification status has been studied as a potential prognostic indicator. The majority of the 
early reports showed that amplification of the EGFR was associated with a poorer prognosis 
than that associated with non-amplified glioblastomas (Simmons et al., 2001, Shinojima et 
al., 2003). Other studies failed to confirm this relationship. Our study did not show that the 
type of EGFR amplification led to significant differences in survival rates; although, 
interestingly, patients of group GBM-h, with EGFR amplification type dmin survived for the 
shortest time.  
6. Conclusion 
Glioblastoma multiforme is characterized by intratumoral heterogeneity in both 
histomorphological and genetic changes, displaying a wide variety of numerical 
chromosome aberrations, the most common of which are trisomy 7 and monosomy 10. The 
amplification of the epidermal growth factor receptor (EGFR) gene is the most frequently 
reported genetic abnormality. 
Our studies about histopathological and genetical characterization of glioblastoma 
multiforme suggest that, in primary glioblastomas, there exists a subgroup of cases closely 
linked with EGFR amplification. However, there is another subgroup of cases without EGFR 
amplification with some different clinical and genetic characteristics. This second group 
might include the increased activation or expression of other growth factor receptors 
observed in these tumors such as PDGFR or IGFR, although they are only amplified in a low 
percentage of cases.  
Furthermore, we proposed that EGFR amplification is an important and frequent pathway 
in glioblastomas. This amplification is expressed as dmin in a subset of glioblastoma, but we 
have observed another type of amplification of the EGFR gene. This is seen at chromosome 
level as distributed insertions of this gene in chromosome 7 itself. Detection of this pattern 
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of amplification of EGFR may further improve the prognostic value of genomic diagnosis of 
this disease.  
Since amplification is often associated with poor prognosis and is a mechanism of resistance 
to therapies, it will be important to identify the genes or pathways (or both) that promote 
amplification in tumors, so that they might be targeted as part of a combination therapy to 
prevent the evolution of resistance to drugs designed to arrest or eradicate the tumor.  
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